Insmed Inc.

7 trials 2 recruiting Commercial sponsor

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

2 Recruiting

5 Completed trials

15 Countries active

5 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 2 Phase II/III: 2 Phase II: 3

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Pulmonary arterial hypertension 2 Sinusitis noninfective 1

Top IMPs

TREPROSTINIL PALMITIL 4 BRENSOCATIB 2 AMIKACIN 1 AZITHROMYCIN 1 ETHAMBUTOL HYDROCHLORIDE 1

All trials

7 total

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Trepostini… Recruiting

2025-521558-40-00 Phase III 12 countries TREPROSTINIL PALMITIL
OLE study in participants with pulmonary arterial hypertension Recruiting

2023-505539-11-00 Phase II/III 6 countries TREPROSTINIL PALMITIL
A Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa Ended

2024-515959-38-00 Phase II 7 countries BRENSOCATIB
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Ended

2022-502481-24-00 Phase II 11 countries BRENSOCATIB
A study to evaluate the effects of Treprostinil Palmitil Inhalation Powder in participants with Pulmonary Hypertension with Interstitial Lun… Ended

2023-505540-19-00 Phase II/III 4 countries TREPROSTINIL PALMITIL
Treprostinil Palmitil Inhalation Powder for Pulmonary Arterial Hypertension Ended

2023-505541-99-00 Phase II 6 countries TREPROSTINIL PALMITIL
A study to evaluate the effects of ALIS based treatment in patients newly diagnosed with nontuberculous mycobacterial lung infection caused … Ended

2023-505273-33-00 Phase III 11 countries AMIKACIN; AZITHROMYCIN; ETHAMBUTOL HYDROCHLORIDE

Showing 1–7 of 7 trials

← All sponsors A–Z